PLRX
Pliant Therapeutics, Inc.
$0.86
-0.20%
2026-10-23
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Key Fundamentals
Forward P/E
-0.84
EPS (TTM)
$-1.50
ROE
-50.3%
Profit Margin
0.0%
Debt/Equity
19.56
Price/Book
0.46
Beta
1.28
Market Cap
$66.9M
Avg Volume (10D)
374K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$1.23
60D Low
$0.83
Avg Volume
410K
Latest Close
$0.86
Get breakout alerts for PLRX
Sign up for Breakout Scanner to receive daily notifications when PLRX triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Pliant Therapeutics, Inc. (PLRX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors PLRX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. PLRX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.